Blog Date 18 February, 2026

What Role Do EP Impurity Standards Play in Quetiapine?

What Role Do EP Impurity Standards Play in Quetiapine?

In the pharmaceutical industry, the quality of the final product is of the highest priority, especially when the product is meant for treating mental illnesses. Quetiapine, an antipsychotic that is used to treat schizophrenia, bipolar disorder, and major depressive episodes, is one such product that needs to meet the regulatory requirements before being made available to the end user. Among the regulatory requirements that the pharmaceutical industry needs to meet, impurity profiling is one of the key ones. Impurity profiling is conducted in accordance with the European Pharmacopoeia’s impurity standards, which help ensure that the final product is safe for use and effective in the long run.

EP Impurity Standards are not just regulatory requirements that the pharmaceutical industry needs to meet. Rather, they are tools that the pharmaceutical industry and the testing labs they hire need to determine the safety of Quetiapine formulations. 

In the following blog, we will see the role that impurity standards play in the pharmaceutical industry and why the pharmaceutical industry needs to source impurity standards like Impurity P, F, and G from certified sources.

Why Impurity Standards Matter in Drug Manufacturing?

Manufacturing active pharmaceutical ingredients (APIs) like Quetiapine involves complex chemical processes. Throughout these processes, structurally related substances, commonly referred to as impurities, may emerge. Some arise due to incomplete reactions, while others form through degradation or storage.

Although these trace substances may initially appear harmless, they can compromise the drug’s stability, efficacy, or even patient safety. This is why regulators demand detailed identification, quantification and control of such impurities within safe thresholds.

EP Impurity Standards play a central role here. These validated reference substances come with certificates of analysis, purity data and batch details. They enable laboratories to:

  • Calibrate instruments such as HPLC or LC-MS effectively
  • Verify analytical method validity
  • Identify and quantify impurities in Quetiapine formulations
  • Maintain consistency across batches and manufacturing sites

How EP Impurity Standards Ensure Regulatory Compliance?

To market a Quetiapine product in Europe, a manufacturer must meet Ph. Eur. standards. The Quetiapine monograph specifies acceptable impurity limits and outlines testing procedures with system suitability criteria. These Impurity Standards act as benchmarks to demonstrate compliance for drug substances and finished formulations.

Precise impurity analysis is vital for:

  • Pre release testing
  • Stability studies
  • Bioequivalence submissions
  • Process validation
  • Regulatory audits and change control

Moreover, certified reference standards simplify communication with regulatory authorities such as EMA, EDQM and WHO. Analytical reports referencing certified Impurity Standards are more likely to be accepted with minimal objections during dossier review.

Category: Impurity Standards

Subcategory: Quetiapine

The EP lists several related substances for Quetiapine. Among the most critical are:

Impurity P is a byproduct that forms during the alkylation step in the production process. It has a different profile from the main product and its levels must not exceed the specified limit.

Impurity F is generally seen in the side chains in the production process. It must be monitored accurately during the process, especially during the stress tests.

This impurity is often encountered during intermediate synthesis stages. The standard assists laboratories in their detection and quantification during release testing or process validation.

Practical Benefits for Manufacturers and Labs

  • Utilising EP Impurity Standards delivers tangible advantages in pharmaceutical development:
  • Reduces rework by improving data consistency
  • Enhances traceability and quality documentation
  • Accelerates market approvals through regulatory compliance
  • Standardises results across facilities and analysts
  • Decreases product recalls linked to unacceptable impurity levels

Conclusion

Precision begins with the right reference material. Chemicea understands the urgency of compliance without slowing down innovation. As an ISO and GMP certified leader, Chemicea serves over 2000+ clients in more than 35+  countries. Its 7000 square foot R&D centre supplies high purity reference standards with complete documentation, quality assurance and global regulatory compliance.

Next Blog